Sep 12, 2022 / 08:15PM GMT
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity Analyst
All right. Good afternoon, everyone. My name is Tejas Savant, and I'm the life science tools and diagnostics analyst at Morgan Stanley. It's my pleasure to host Avantor this afternoon. And with me is Michael Stubblefield. In the audience, we have Tom Szlosek, and CJ is out there somewhere as well. So welcome, guys, and thanks for doing this.
Before we get started, just a quick disclaimer that I need to read off over here. For important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. And if you have any questions, do reach out to your Morgan Stanley sales rep.
Questions and Answers:
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity AnalystSo with that, Michael, it's been a very dynamic year for Avantor with a lot of moving pieces. So as you sit here today, what are some of your reflections on the business performance year-to-date?
Michael Stubblefield - Avantor, Inc.
Trustpilot
